A T Van Oosterom
Overview
Explore the profile of A T Van Oosterom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
254
Citations
8842
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huygh G, Clement P, Dumez H, Schoffski P, Wildiers H, Selleslach J, et al.
Sarcoma
. 2007 May;
2006:56282.
PMID: 17496996
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as...
2.
Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A, et al.
Eur J Cancer
. 2005 Dec;
42(1):50-4.
PMID: 16330205
EORTC protocol 30924 is an international randomized trial reporting a 7.3 year update of a 2 weekly regimen of high-dose intensity chemotherapy with M-VAC plus granulocyte colony stimulating factor (HD-M-VAC)...
3.
Fossa S, Paluchowska B, Horwich A, Kaiser G, De Mulder P, Koriakine O, et al.
Br J Cancer
. 2005 Oct;
93(11):1209-14.
PMID: 16251877
New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in intermediate...
4.
Guetens G, Prenen H, De Boeck G, Van Dongen W, Esmans E, Lemiere F, et al.
J Chromatogr A
. 2005 Jul;
1082(1):2-5.
PMID: 16038188
The development of an on-column focusing gradient capillary LC method coupled to tandem mass spectrometry (quadrupole-linear ion trap) for the quantitative determination of the anticancer agent ZD1839 (Gefitinib, Iressa) in...
5.
Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom A, Sciot R
Histopathology
. 2005 Jun;
47(1):41-7.
PMID: 15982322
Aims: The diagnosis of gastrointesinal stromal tumours (GISTs) is widely based on morphological features and KIT (CD117) immunoreactivity. Most patients with advanced GISTs show a major clinical response after treatment...
6.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge M, Eskens F, et al.
J Clin Oncol
. 2005 Feb;
23(4):889-98.
PMID: 15681535
Purpose: To assess the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary antitumor activity of oral irinotecan given in combination with capecitabine to patients with advanced, refractory solid tumors. Patients...
7.
Landuyt B, Prenen H, Debiec-Rychter M, Sciot R, de Bruijn E, Van Oosterom A
Amino Acids
. 2004 Nov;
27(3-4):335-7.
PMID: 15549490
Gastrointestinal stromal tumors (GISTs) arise from the interstitial cells of Cajal through gain of function mutations of the oncogene KIT. Imatinib offers the first effective treatment for patients with GISTs,...
8.
Wachters F, Groen H, Maring J, Gietema J, Porro M, Dumez H, et al.
Br J Cancer
. 2004 May;
90(12):2261-7.
PMID: 15150611
In MAG-camptothecin (MAG-CPT), the topoisomerase inhibitor camptothecin is linked to a water-soluble polymer. Preclinical experiments showed enhanced antitumour efficacy and limited toxicity compared to camptothecin alone. Prior phase I trials...
9.
de Jonge M, Droz J, Paz-Ares L, Van Oosterom A, de Wit R, Chollet P, et al.
Invest New Drugs
. 2004 May;
22(3):329-33.
PMID: 15122081
Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...
10.
Giaccone G, Gonzalez-Larriba J, Van Oosterom A, Alfonso R, Smit E, Martens M, et al.
Ann Oncol
. 2004 Apr;
15(5):831-8.
PMID: 15111354
Background: The aim of this study was to investigate the tolerability, pharmacokinetic interaction and antitumor activity of gefitinib ("Iressa", ZD1839), an orally active, selective epidermal growth factor receptor tyrosine kinase...